Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-03-28
Schrodinger, Inc.
Schrödinger sells molecular-design software and informatics to life-science customers and uses the same computational platform in collaborations and internal drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Hosted reset with royalty-backed upside
The core question is whether near-term accounting noise is hiding a higher-quality software model. If the hosted shift holds ACV growth and therapeutics value is externalized through partners, today's valuation looks too low for the business quality by 2031.

Analysis

Thesis
Schrödinger can turn a messy hosted transition into a cleaner recurring software business while keeping therapeutics upside capital-light; if LiveDesign becomes the trusted operating layer for AI-assisted discovery, the market can rerate the company from niche discovery tools vendor to durable workflow software with royalty optionality.
Last Economy Alignment
AI should expand demand for computational discovery and make governed, auditable workflows more valuable, and LiveDesign plus the physics stack give Schrödinger a real control point. But it does not own the compute or wet-lab bottlenecks, and large pharma can still internalize parts of the stack.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.3x (from 5 most recent analyses)
Reasoning
The upside comes from a quality change more than a pure volume story. If the hosted shift proves economic, ACV keeps compounding, and new modules plus partner-facing workflows deepen adoption, investors can value the business more like durable scientific workflow software with capital-light royalty upside. The ceiling stays below hypergrowth because pharma sales cycles are slow and the pipeline is no longer being pushed aggressively in-house.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The biggest risk is that the hosted transition proves to be accounting noise without stronger economic retention, upsell, or pricing power. The second risk is that therapeutics optionality depends on external partners rather than internal continuation, which caps control over timing and value capture. AI is a tailwind for demand, but it also raises the chance that parts of the modeling stack become easier to substitute.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.47
They sit inside drug discovery teams' daily workflow, which matters more as AI creates more candidate ideas and teams need a trusted place to organize, compare, and hand off decisions. The risk is that pharma builds more of this stack in-house or cheaper AI tools turn the science layer into a feature instead of a moat.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$22.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case